Angiotech announces results for the fourth quarter ended Decembe...(ic net (loss) income per common ...)
| HOME >> BIOLOGY >> TECHNOLOGY |
ic net (loss)
income per common
share from
continuing
operations (0.20) (0.09) (0.06) 0.14
Diluted net (loss)
income per
common share from
continuing
operations (0.20) (0.09) (0.06) 0.14
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average
shares outstanding
(000's) - basic 85,030 85,030 84,984 84,984
Weighted average
shares outstanding
(000's) - diluted 85,030 85,030 85,547 85,547
-------------------------------------------------------------------------
-------------------------------------------------------------------------
a. One time revenue gain resulting from the up-front monetization of a
royalty revenue stream to be received from our collaboration and
distribution partnership with Orthovita.
b. Amounts accrued for costs incurred, and potential future costs,
related to our offer to accept returns of Contour Threads brand
product as part of consolidation and discontinuation of the Contour
Threads brand name, coincident with the launch of our Quill SRS brand
name.
c. Non-recurring revenue relating to selected licence agreements, net of
licence fees due to licensors.
d. Change in estimate of accounting for excess and obsolete inventory
resulting from the alignment during the fourth quarter of 2007 of
inventory policies across our various manufacturing operations.
e. Stock-based compensation expense.
f. Selling, general and administrative adjustments:
---------------------------------------------------------------------
'/>"/>
| SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |